Our Lumi Series tests examine genes that are associated with hereditary cancers for risk assessment, cancer screening and
matching with targeted therapy at 99% sensitivity.
Available internationally outside the USA.
LumiRISK provides comprehensive coverage with assessment of 45 genes related to 11 cancers to assess the risk of developing hereditary cancer and can enable patients to take better preventive action.
LumiRISK may be suitable for individuals who wish to be informed of their cancer risk especially those who have a family history of cancer.
LumiFOCUS examines genes associated with specific hereditary cancers based on cancer-specific panels.
LumiFOCUS may be suitable for individuals who wish to be informed of their cancer risk especially those who have relative diagnosed with the same type of cancer at a younger age.
LumiTHERA analyzes 17 guideline-recommended genes (including those in the Homologous Recombination Repair (HRR) pathway) to match actionable results with US FDA-approved targeted therapies.
LumiTHERA may be suitable for patients who have breast, ovarian, prostate, pancreatic or colorectal cancer that may be inherited.